ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Wednesday

Key Points

• ArriVent BioPharma is set to release its Q2 2025 earnings on August 13th, with analysts forecasting an earnings per share of ($0.70) for the quarter.
• The company reported ($1.90) earnings per share in its last quarterly results, significantly missing expectations by ($1.24).
• Analysts' ratings for ArriVent BioPharma vary, with an average rating of "Moderate Buy" and a target price of $39.29, while one analyst has issued a sell rating.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($1.24). On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Price Performance

ArriVent BioPharma stock traded down $0.55 during trading hours on Friday, hitting $17.99. The company had a trading volume of 134,339 shares, compared to its average volume of 246,032. The firm has a market cap of $615.44 million, a PE ratio of -4.77 and a beta of 1.17. ArriVent BioPharma has a one year low of $15.47 and a one year high of $36.37. The firm has a 50-day moving average of $21.89 and a 200 day moving average of $21.83.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AVBP. The Goldman Sachs Group upgraded shares of ArriVent BioPharma to a "buy" rating and set a $33.00 target price on the stock in a research report on Thursday, July 10th. Guggenheim restated a "buy" rating and set a $45.00 target price on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of ArriVent BioPharma in a research report on Tuesday, July 22nd. Jones Trading began coverage on shares of ArriVent BioPharma in a research report on Tuesday, May 20th. They set a "buy" rating and a $40.00 target price on the stock. Finally, Oppenheimer restated an "outperform" rating and set a $44.00 target price (up previously from $39.00) on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $39.29.

Institutional Trading of ArriVent BioPharma

Several large investors have recently made changes to their positions in the company. Woodline Partners LP boosted its position in shares of ArriVent BioPharma by 0.4% during the 1st quarter. Woodline Partners LP now owns 146,373 shares of the company's stock worth $2,706,000 after acquiring an additional 576 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in ArriVent BioPharma in the 1st quarter valued at approximately $266,000. Finally, Jane Street Group LLC bought a new position in ArriVent BioPharma in the 1st quarter valued at approximately $189,000. Institutional investors and hedge funds own 9.48% of the company's stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.